University of California San Francisco | About UCSF | UCSF Benioff Children's Hospital San Francisco
Search Site | Find a Doctor

Alexander Gottschalk, Ph.D., M.D.

Director of Cyberknife Radiosurgery

Dr. Alexander Gottschalk, an expert in radiation treatment, is director of the UCSF Cyberknife Radiosurgery Program. Using the Cyberknife, Gottschalk treats cancer of the brain and spine; breast, chest and lung; abdomen; kidney; and pelvis. In addition, he treats urologic cancer such as bladder and prostate cancer; gastrointestinal cancer such as pancreas cancer; soft tissue tumors such as sarcoma and thoracic cancer such as lung cancer, using other radiation treatments.

Gottschalk earned a medical degree and Ph.D. at the University of Chicago and completed a residency in radiation oncology at UCSF Medical Center. He is the recipient of numerous awards and grants, including the National Institutes of Health National Research Service Award, Medical Scientist Training Program Fellowship, UCSF Helen Diller Family Comprehensive Cancer Center Clinical Investigator Research Program Grant, the RSNA Scholar award and the ASTRO Junior faculty award. He is an associate professor of radiation oncology at UCSF and active in genitourinary research. He is developing clinical trials using inter-operative.

Clinics

Prostate Cancer Center
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Prostate Cancer Risk and Prevention Clinic
1600 Divisadero St, Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Radiation Oncology at Mount Zion
1600 Divisadero St., Basement Level
San Francisco, CA 94143-1708
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-9807
Fax: (415) 353-9884

Hours: Monday to Friday
7 a.m. – 6 p.m.

Radiation Oncology at Parnassus
505 Parnassus Ave, Room L-75
San Francisco, CA 94143-0226
Main Phone: (415) 353-7175
New Patient Appointments: (415) 353-8335
Fax: (415) 353-7281

Hours: Monday to Friday
8 a.m. – 4:30 p.m.

Urologic Surgery and Oncology
1600 Divisadero St., Third Floor
San Francisco, CA 94115
Phone: (415) 353-7171
Fax: (415) 353-7093

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

More about Alexander Gottschalk

Education

University of Chicago School of Medicine 1996

Residencies

UCSF Medical Center, Radiation Oncology 2001

Selected Research and Publications

  1. Alexander J, Weinberg V, Gottschalk AR, Hsu IC, Shinohara K, Roach M. Pre-plan parameters predict post-implant D90 = 140 Gy for (125)I permanent prostate implants. J Contemp Brachytherapy. 2014 Jun; 6(2):143-53.
  2. Nguyen PL, Aizer A, Assimos DG, D'Amico AV, Frank SJ, Gottschalk AR, Gustafson GS, Hsu IC, McLaughlin PW, Merrick G, Rosenthal SA, Showalter TN, Taira AV, Vapiwala N, Yamada Y, Davis BJ. ACR Appropriateness CriteriaŽ Definitive External-Beam Irradiation in Stage T1 and T2 Prostate Cancer. Am J Clin Oncol. 2014 Jun; 37(3):278-88.
  3. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. Response to drs rogers, hayes, and demanes. Brachytherapy. 2014 Sep-Oct; 13(5):523-5.
  4. Gottschalk A. Commentary on "Toxicity after external beam radiotherapy for prostate cancer: An analysis of late morbidity in men with diabetes mellitus." Kalakota K, Liauw SL, Department of Radiation Oncology, Northwestern Memorial Hospital, Chicago, IL.: Urology 2013;81(6):1196-201. doi: 10.1016/j.urology.2013.01.047. [Epub 2013 Mar 26]. Urol Oncol. 2014 Apr; 32(3):374.
  5. Gottschalk A. Commentary on "Patient-reported outcomes after 3-dimensional conformal, intensity-modulated, or proton beam radiotherapy for localized prostate cancer." Gray PJ, Paly JJ, Yeap BY, Sanda MG, Sandler HM, Michalski JM, Talcott JA, Coen JJ, Hamstra DA, Shipley WU, Hahn SM, Zietman AL, Bekelman JE, Efstathiou JA. Harvard Radiation Oncology Program, Boston, MA.: Cancer 2013;119(9):1729-35. doi: 10.1002/cncr.27956. [Epub 2013 Feb 22]. Urol Oncol. 2014 Apr; 32(3):373-4.
  6. Gottschalk A. Commentary on "A systematic review of stereotactic radiotherapy ablation for primary renal cell carcinoma." Siva S, Pham D, Gill S, Corcoran NM, Foroudi F. Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Victoria, Australia.: BJU Int 2012;110(11 Pt B):E737-43. doi: 10.1111/j.1464-410X.2012.11550.x. [Epub 2012 Oct 29]. Urol Oncol. 2014 Apr; 32(3):374-5.
  7. Garcia MM, Gottschalk AR, Brajtbord J, Konety BR, Meng MV, Roach M, Carroll PR. Endoscopic gold fiducial marker placement into the bladder wall to optimize radiotherapy targeting for bladder-preserving management of muscle-invasive bladder cancer: feasibility and initial outcomes. PLoS One. 2014; 9(3):e89754.
  8. Anwar M, Weinberg V, Chang AJ, Hsu IC, Roach M, Gottschalk A. Hypofractionated SBRT versus conventionally fractionated EBRT for prostate cancer: comparison of PSA slope and nadir. Radiat Oncol. 2014; 9(1):42.
  9. Gottschalk A. Commentary on "Secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: Incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13]. Urol Oncol. 2014 Feb; 32(2):209.
  10. Hsu IC, Yamada Y, Assimos DG, D'Amico AV, Davis BJ, Frank SJ, Gottschalk AR, Gustafson GS, McLaughlin PW, Nguyen PL, Rosenthal SA, Taira AV, Vapiwala N, Merrick G. ACR Appropriateness Criteria high-dose-rate brachytherapy for prostate cancer. Brachytherapy. 2014 Jan-Feb; 13(1):27-31.
  11. Crehange G, Krishnamurthy D, Cunha JA, Pickett B, Kurhanewicz J, Hsu IC, Gottschalk AR, Shinohara K, Roach M, Pouliot J. Cold spot mapping inferred from MRI at time of failure predicts biopsy-proven local failure after permanent seed brachytherapy in prostate cancer patients: Implications for focal salvage brachytherapy. Radiother Oncol. 2013 Nov; 109(2):246-50.
  12. Descovich M, Carrara M, Morlino S, Pinnaduwage DS, Saltiel D, Pouliot J, Nash MB, Pignoli E, Valdagni R, Roach M, Gottschalk AR. Improving plan quality and consistency by standardization of dose constraints in prostate cancer patients treated with CyberKnife. J Appl Clin Med Phys. 2013; 14(5):162-72.
  13. Chen CP, Weinberg V, Shinohara K, Roach M, Nash M, Gottschalk A, Chang AJ, Hsu IC. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int J Radiat Oncol Biol Phys. 2013 Jun 1; 86(2):324-9.
  14. Eberhardt SC, Carter S, Casalino DD, Merrick G, Frank SJ, Gottschalk AR, Leyendecker JR, Nguyen PL, Oto A, Porter C, Remer EM, Rosenthal SA. ACR Appropriateness Criteria prostate cancer--pretreatment detection, staging, and surveillance. J Am Coll Radiol. 2013 Feb; 10(2):83-92.
  15. Pejavar S, Yom SS, Hwang A, Speight J, Gottschalk A, Hsu IC, Roach M, Xia P. Computer-assisted, atlas-based segmentation for target volume delineation in whole pelvic IMRT for prostate cancer. Technol Cancer Res Treat. 2013 Jun; 12(3):199-206.
  16. Gottschalk A, Brodner G, Van Aken HK, Ellger B, Althaus S, Schulze HJ. Can regional anaesthesia for lymph-node dissection improve the prognosis in malignant melanoma? Br J Anaesth. 2012 Aug; 109(2):253-9.
  17. Hsu CC, Hsu H, Pickett B, Crehange G, Hsu IC, Dea R, Weinberg V, Gottschalk AR, Kurhanewicz J, Shinohara K, Roach M. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int J Radiat Oncol Biol Phys. 2013 Feb 1; 85(2):370-7.
  18. Shiao SL, Sahgal A, Hu W, Jabbari S, Chuang C, Descovich M, Hsu IC, Gottschalk AR, Roach M, Ma L. Temporal compartmental dosing effects for robotic prostate stereotactic body radiotherapy. Phys Med Biol. 2011 Dec 21; 56(24):7767-75.
  19. Vidal-Gadea A, Topper S, Young L, Crisp A, Kressin L, Elbel E, Maples T, Brauner M, Erbguth K, Axelrod A, Gottschalk A, Siegel D, Pierce-Shimomura JT. Caenorhabditis elegans selects distinct crawling and swimming gaits via dopamine and serotonin. Proc Natl Acad Sci U S A. 2011 Oct 18; 108(42):17504-9.
  20. Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach M, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012 Jan 1; 82(1):228-34.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.